FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294131778> ?p ?o ?g. }

• W4294131778 endingPage "4279" @default.
• W4294131778 startingPage "4279" @default.
• W4294131778 abstract "This study investigated the safety and antitumor activity of aromatase inhibitors (AI) with immune checkpoint inhibitor (ICI) pembrolizumab in patients with hormone receptor positive (HR+) human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) in a phase II study with a safety lead-in (NCT 02648477). Patients received pembrolizumab plus AI up to 2 years or until confirmed progression or unacceptable toxicity. Key eligibility criteria were HR+ HER2− MBC; RECIST v1.1 measurable disease; adequate organ function; and ECOG 0-1. Primary endpoints were safety and overall response rate. A 3-at-risk design was used for the safety lead-in with a targeted accrual of 20 patients. Grade 2 adverse events (AEs) included 35% fatigue, 20% rash, and 10% hot flashes. Grade 3 immune-related AEs (irAEs) related to pembrolizumab included 5% elevated AST/ALT, 5% rash, and 5% lymphopenia. Two (10%) patients had partial responses, three (15%) had stable disease, and 15 (75%) had progression of disease. Median progression-free survival was 1.8 months (95% CI 1.6, 2.6), median overall survival was 17.2 months (95% CI 9.4, NA), and median follow-up time was 40.1 months (range 31.3–46.8 months). The combination was well tolerated, but clinical activity was comparable to AI alone." @default.
• W4294131778 created "2022-09-02" @default.
• W4294131778 creator A5004500382 @default.
• W4294131778 creator A5005344580 @default.
• W4294131778 creator A5005473474 @default.
• W4294131778 creator A5008678762 @default.
• W4294131778 creator A5011540763 @default.
• W4294131778 creator A5013275278 @default.
• W4294131778 creator A5017695332 @default.
• W4294131778 creator A5019170187 @default.
• W4294131778 creator A5023917993 @default.
• W4294131778 creator A5027237687 @default.
• W4294131778 creator A5037942451 @default.
• W4294131778 creator A5041448171 @default.
• W4294131778 creator A5066313327 @default.
• W4294131778 creator A5074603645 @default.
• W4294131778 creator A5077481880 @default.
• W4294131778 creator A5082432682 @default.
• W4294131778 creator A5082853715 @default.
• W4294131778 creator A5087409546 @default.
• W4294131778 date "2022-09-01" @default.
• W4294131778 modified "2023-09-26" @default.
• W4294131778 title "Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer" @default.
• W4294131778 cites W2057187391 @default.
• W4294131778 cites W2085133181 @default.
• W4294131778 cites W2120431466 @default.
• W4294131778 cites W2143459396 @default.
• W4294131778 cites W2160074846 @default.
• W4294131778 cites W2167188058 @default.
• W4294131778 cites W2290950904 @default.
• W4294131778 cites W2347070489 @default.
• W4294131778 cites W2528767298 @default.
• W4294131778 cites W2542773270 @default.
• W4294131778 cites W2552099557 @default.
• W4294131778 cites W2617437931 @default.
• W4294131778 cites W2750328162 @default.
• W4294131778 cites W2766016994 @default.
• W4294131778 cites W2791308824 @default.
• W4294131778 cites W2897422388 @default.
• W4294131778 cites W2914345456 @default.
• W4294131778 cites W2944392072 @default.
• W4294131778 cites W2945564879 @default.
• W4294131778 cites W2953080297 @default.
• W4294131778 cites W3000078203 @default.
• W4294131778 cites W3003043114 @default.
• W4294131778 cites W3024815097 @default.
• W4294131778 cites W3036479961 @default.
• W4294131778 cites W3088289897 @default.
• W4294131778 cites W3109853980 @default.
• W4294131778 cites W3139239897 @default.
• W4294131778 cites W3141372695 @default.
• W4294131778 cites W3181200691 @default.
• W4294131778 doi "https://doi.org/10.3390/cancers14174279" @default.
• W4294131778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36077811" @default.
• W4294131778 hasPublicationYear "2022" @default.
• W4294131778 type Work @default.
• W4294131778 citedByCount "1" @default.
• W4294131778 countsByYear W42941317782023 @default.
• W4294131778 crossrefType "journal-article" @default.
• W4294131778 hasAuthorship W4294131778A5004500382 @default.
• W4294131778 hasAuthorship W4294131778A5005344580 @default.
• W4294131778 hasAuthorship W4294131778A5005473474 @default.
• W4294131778 hasAuthorship W4294131778A5008678762 @default.
• W4294131778 hasAuthorship W4294131778A5011540763 @default.
• W4294131778 hasAuthorship W4294131778A5013275278 @default.
• W4294131778 hasAuthorship W4294131778A5017695332 @default.
• W4294131778 hasAuthorship W4294131778A5019170187 @default.
• W4294131778 hasAuthorship W4294131778A5023917993 @default.
• W4294131778 hasAuthorship W4294131778A5027237687 @default.
• W4294131778 hasAuthorship W4294131778A5037942451 @default.
• W4294131778 hasAuthorship W4294131778A5041448171 @default.
• W4294131778 hasAuthorship W4294131778A5066313327 @default.
• W4294131778 hasAuthorship W4294131778A5074603645 @default.
• W4294131778 hasAuthorship W4294131778A5077481880 @default.
• W4294131778 hasAuthorship W4294131778A5082432682 @default.
• W4294131778 hasAuthorship W4294131778A5082853715 @default.
• W4294131778 hasAuthorship W4294131778A5087409546 @default.
• W4294131778 hasBestOaLocation W42941317781 @default.
• W4294131778 hasConcept C121608353 @default.
• W4294131778 hasConcept C126322002 @default.
• W4294131778 hasConcept C143998085 @default.
• W4294131778 hasConcept C197934379 @default.
• W4294131778 hasConcept C2775930923 @default.
• W4294131778 hasConcept C2776166826 @default.
• W4294131778 hasConcept C2776694085 @default.
• W4294131778 hasConcept C2777701055 @default.
• W4294131778 hasConcept C2778504769 @default.
• W4294131778 hasConcept C2778570526 @default.
• W4294131778 hasConcept C2780057760 @default.
• W4294131778 hasConcept C2780739268 @default.
• W4294131778 hasConcept C530470458 @default.
• W4294131778 hasConcept C71924100 @default.
• W4294131778 hasConcept C90924648 @default.
• W4294131778 hasConceptScore W4294131778C121608353 @default.
• W4294131778 hasConceptScore W4294131778C126322002 @default.
• W4294131778 hasConceptScore W4294131778C143998085 @default.
• W4294131778 hasConceptScore W4294131778C197934379 @default.
• W4294131778 hasConceptScore W4294131778C2775930923 @default.

• next